LAURA LEVINGSTON: Open Payments
NPI 1962022160 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,784 in 196 payments from 27 companies in 2025. Trend: 2023 $4,889 · 2024 $4,958 · 2025 $4,784
Food & beverage: $4,784
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 52 | $1,043 |
| ABBVIE INC. | 31 | $761 |
| Lilly USA, LLC | 10 | $413 |
| UCB, Inc. | 14 | $369 |
| GlaxoSmithKline, LLC. | 10 | $315 |
| Janssen Biotech, Inc. | 18 | $270 |
| Novo Nordisk Inc | 2 | $200 |
| ANI Pharmaceuticals, Inc. | 13 | $189 |
| Novartis Pharmaceuticals Corporation | 9 | $183 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $133 |
Products named: SKYRIZI, Bimzelx, TAVNEOS, RINVOQ, KRYSTEXXA, TREMFYA, BENLYSTA, UPLIZNA.
Industry payments across CA — which companies pay providers there.
